Rapastinel
Also known as: GLYX-13, GLYX‑13, NRX-1074, Rapastinel, Thr-Pro-Pro-Thr-NH2
Source Rapastinel at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Rapastinel (GLYX‑13) is a tetrapeptide under development as a rapid‑acting antidepressant for major depressive disorder; it has shown efficacy in phase II trials but is not yet approved.
Mechanism of Action
Modulates NMDA receptor function by acting as a partial agonist at the glycine co‑agonist site, enhancing synaptic plasticity and producing rapid antidepressant effects
Routes of Administration
Goals & Uses
- Treatment-resistant depressionPsychiatryLow
- Rapid antidepressant effectPsychiatryLow
- Major Depressive DisorderDepressionModerate
- Synaptic plasticity enhancementNeuroscience / ResearchModerate
- Major Depressive Disorder (MDD) treatmentPsychiatry / AntidepressantModerate
Contraindications
- History of psychotic disordersPsychiatricModerate
- Known hypersensitivity to rapastinel or excipientsAllergyHigh
Adverse Effects
- HeadacheNeurologicCommonPain in the head or upper neck
- Transient hypertensionCardiovascularUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Dissociative symptomsPsychiatric/NeurologicalRare
- Infusion site reactionsLocalUncommon
- DizzinessNeurologicCommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Other NMDA receptor modulators (e.g., ketamine, memantine)Moderate
- Antidepressants (SSRIs, SNRIs, MAOIs)Low
- MemantineLow
- KetamineModerate
Population Constraints
- Severe renal or hepatic impairmentOrgan FunctionRelative
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trials ongoing; no EMA approval
- United StatesInvestigationalUnder clinical investigation; not FDA‑approved
- United KingdomInvestigationalBeing evaluated in UK clinical studies
Investigational drug; not approved for any indication in the US, EU or UK.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Rapastinel?
Rapastinel (GLYX‑13) is a tetrapeptide under development as a rapid‑acting antidepressant for major depressive disorder; it has shown efficacy in phase II trials but is not yet approved.
What is Rapastinel used for?
Rapastinel is educationally associated with: Treatment-resistant depression, Rapid antidepressant effect, Major Depressive Disorder, Synaptic plasticity enhancement, Major Depressive Disorder (MDD) treatment. Educational only — not medical advice.
How is Rapastinel administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Rapastinel?
Reported adverse effects include: Headache, Transient hypertension, Nausea, Dissociative symptoms, Infusion site reactions, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Rapastinel?
Recorded contraindications: History of psychotic disorders, Known hypersensitivity to rapastinel or excipients. Consult a qualified clinician before use.